Hemagen (US) gets Chagas approval:
This article was originally published in Clinica
Hemagen (US) has received FDA approval to market its Chagas' disease ELISA. Chagas' disease, a progressively debilitating, insect-borne parasitic disease, can be transmitted through blood transfusions and usually kills its victims within ten years. Testing is routine in Latin American blood banks, but not in the US. The test is already marketed in South America by German major Boehringer Mannheim (see Clinica No 583, p 3), and in Brazil under Hemagen's own label. As many as 7% of the South American population have Chagas' disease.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.